ÂÜÀòÂÒÂ×

Qing Xu is a seasoned professional in the field of cell therapy and immunology, currently serving as a Manager, Senior Engineer I - II at Bristol Myers Squibb since March 2021, where responsibilities include supporting the development and commercialization of lentiviral vectors and CAR-T products, as well as leading process control strategies. Prior experience includes a position as a Senior Scientist at Legend Biotech, focusing on TCR-T cell therapy pipelines, and an ORISE Fellowship at the FDA. Qing also held a Postdoctoral Fellowship at the National Cancer Institute, concentrating on CAR-T cell generation and T cell research. Academic credentials include a PhD in Pathology and Cell Biology from Nanjing Medical University.